DDInter438 DDInter1676
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Conivaptan {u} (Compound) resembles {v} (Compound) Tolvaptan
Conivaptan {u} (Compound) resembles {v} (Compound) Deferasirox
Conivaptan {u} (Compound) binds {v} (Gene) AVPR1A
Conivaptan {u} (Compound) is included by {v} (Pharmacologic Class) Antidiuretic Hormone Antagonists
Conivaptan {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Conivaptan (Compound) resembles Tolvaptan (Compound)
Conivaptan (Compound) resembles Deferasirox (Compound)
Conivaptan (Compound) binds AVPR1A (Gene)
Conivaptan (Compound) is included by Antidiuretic Hormone Antagonists (Pharmacologic Class)
Conivaptan (Compound) causes Feeling abnormal (Side Effect)
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Conivaptan may lead to a major life threatening interaction when taken with Naloxegol